Sun Pharma launches medication for Erosive Esophagitis

Sun Pharmaceutical Industries has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VvDg7mk
via IFTTT